PT‐141 Melanocortin Research Overview
PT‐141 is a high-purity, research-grade synthetic peptide derived from alpha‐melanocyte‐stimulating hormone (α‐MSH), developed to investigate melanocortin receptor signaling in sexual function, energy balance, and immune modulation. It offers a centrally acting model for studying libido and arousal pathways distinct from vascular or hormonal mechanisms.
Molecular Composition and Mechanistic Profile
Identity: PT‐141 (Bremelanotide), a cyclic heptapeptide melanocortin analogue.
Mechanistically, PT‐141:
Acts as an agonist at melanocortin‐4 (MC4R) and melanocortin‐1 (MC1R) receptors, with primary relevance to sexual behavior and energy balance through MC4R in the CNS and additional roles in pigmentation, inflammation, pain, and infection via MC1R.
Targets hypothalamic and limbic brain regions such as the medial preoptic area (mPOA), modulating neural circuits involved in sexual desire and arousal.
Differs from phosphodiesterase‐5 (PDE‐5) inhibitors by acting centrally rather than primarily on peripheral vascular smooth muscle, making it a model for centrally mediated hypoactive sexual desire states.
These properties make PT‐141 an important tool for dissecting CNS melanocortin signaling in both behavioral and metabolic contexts.
Integrated Research Applications
PT‐141 is used across several experimental domains centered on melanocortin biology. Representative areas include:
Sexual function and behavior: Preclinical and clinical models of hypoactive sexual desire disorder (HSDD), erectile function, and arousal in both males and females, focusing on central arousal circuitry rather than peripheral
hemodynamics.
Energy balance and obesity: Exploration of MC4R‐driven appetite and energy expenditure pathways, where PT‐141 provides a means to study
melanocortin-based interventions in obesity and metabolic regulation.
Immune and inflammatory response: MC1R involvement in pain, inflammation, kidney pathology, and infectious spread provides a rationale for using PT‐141 to probe melanocortin‐linked immunomodulation.
Together, these models allow investigators to map how melanocortin receptor engagement influences behavior, metabolism, and immune status.
Analytical Validation, Formulation, and Care
Research PT‐141 products are typically supplied as lyophilized peptide in defined content per vial (e.g., 10 mg or 3 mg × 10 vials). Key quality and handling features include:
Purity: >98–99% confirmed by HPLC, often with COA available on request.
Formulation: Shipped as lyophilized or powder form, requiring reconstitution to
liquid with appropriate sterile diluent prior to research use.
Product notes emphasize that dosing instructions are not provided and that materials, while pharmaceutical grade, are for research only.
Storage and Stability
Vendors provide consistent product care guidance for PT‐141:
Store in a cool, dry place away from light when lyophilized.
After constitution, refrigerate the solution to maintain integrity over the short
term.
For longer-term storage, freezing at approximately −20 °C is recommended to preserve peptide structure and activity.
These practices align with general handling standards for small, cyclic research peptides.
NextGenPeps provides PT-141 exclusively for laboratory research use in vitro or in ethically approved animal studies. This compound is not approved for human use and is not intended for ingestion, injection, diagnosis, or treatment outside of controlled research environments.